What is the official website of High-Content Imaging & Analysis | Molecular Devices ?

The official website of High-Content Imaging & Analysis | Molecular Devices is https://www.moleculardevices.com/products/cellular-imaging-systems.

What is High-Content Imaging & Analysis | Molecular Devices's cybersecurity risk score?

High-Content Imaging & Analysis | Molecular Devices has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has High-Content Imaging & Analysis | Molecular Devices experienced?

According to Rankiteo, High-Content Imaging & Analysis | Molecular Devices currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has High-Content Imaging & Analysis | Molecular Devices been affected by any supply chain cyber incidents ?

According to Rankiteo, High-Content Imaging & Analysis | Molecular Devices has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does High-Content Imaging & Analysis | Molecular Devices have SOC 2 Type 1 certification ?

According to Rankiteo, High-Content Imaging & Analysis | Molecular Devices is not certified under SOC 2 Type 1.

Does High-Content Imaging & Analysis | Molecular Devices have SOC 2 Type 2 certification ?

According to Rankiteo, High-Content Imaging & Analysis | Molecular Devices does not hold a SOC 2 Type 2 certification.

Does High-Content Imaging & Analysis | Molecular Devices comply with GDPR ?

According to Rankiteo, High-Content Imaging & Analysis | Molecular Devices is not listed as GDPR compliant.

Does High-Content Imaging & Analysis | Molecular Devices have PCI DSS certification ?

According to Rankiteo, High-Content Imaging & Analysis | Molecular Devices does not currently maintain PCI DSS compliance.

Does High-Content Imaging & Analysis | Molecular Devices comply with HIPAA ?

According to Rankiteo, High-Content Imaging & Analysis | Molecular Devices is not compliant with HIPAA regulations.

Does High-Content Imaging & Analysis | Molecular Devices have ISO 27001 certification ?

According to Rankiteo,High-Content Imaging & Analysis | Molecular Devices is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does High-Content Imaging & Analysis | Molecular Devices operate in ?

High-Content Imaging & Analysis | Molecular Devices operates primarily in the Biotechnology Research industry.

How many employees does High-Content Imaging & Analysis | Molecular Devices have ?

High-Content Imaging & Analysis | Molecular Devices employs approximately None employees people worldwide.

Does High-Content Imaging & Analysis | Molecular Devices own any subsidiaries ?

High-Content Imaging & Analysis | Molecular Devices presently has no subsidiaries across any sectors.

How many LinkedIn followers does High-Content Imaging & Analysis | Molecular Devices have ?

High-Content Imaging & Analysis | Molecular Devices's official LinkedIn profile has approximately 86 followers.

What is the NAICS classification code for High-Content Imaging & Analysis | Molecular Devices ?

High-Content Imaging & Analysis | Molecular Devices is classified under the NAICS code 541714, which corresponds to Research and Development in Biotechnology (except Nanobiotechnology).

Does High-Content Imaging & Analysis | Molecular Devices have a Crunchbase profile ?

No, High-Content Imaging & Analysis | Molecular Devices does not have a profile on Crunchbase.

Does High-Content Imaging & Analysis | Molecular Devices have a LinkedIn profile ?

Yes, High-Content Imaging & Analysis | Molecular Devices maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/high-content-imaging-analysis-molecular-devices.

How many cybersecurity incidents has High-Content Imaging & Analysis | Molecular Devices experienced ?

As of July 24, 2026, Rankiteo reports that High-Content Imaging & Analysis | Molecular Devices has not experienced any cybersecurity incidents.

How many peer or competitor companies does High-Content Imaging & Analysis | Molecular Devices have ?

High-Content Imaging & Analysis | Molecular Devices has an estimated 4,731 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

HIAMD

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

High-Content Imaging & Analysis | Molecular Devices Vendor Cyber Rating & Cyber Score

moleculardevices.com

Add Your Compliance Badge

HIAMD A.I CyberSecurity Scoring

Scoring History

HIAMD

High-Content Imaging & Analysis | Molecular Devices CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

HIAMD Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for HIAMD

Incidents vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for High-Content Imaging & Analysis | Molecular Devices in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for High-Content Imaging & Analysis | Molecular Devices in 2026.

Incident Types HIAMD vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for High-Content Imaging & Analysis | Molecular Devices in 2026.

Incident History - HIAMD (X = Date, Y = Severity)

Loading…

SUBSIDIARY

High-Content Imaging & Analysis | Molecular Devices Subsidiaries

HIAMD

Biotechnology Research

Website: https://www.moleculardevices.com/products/cellular-imaging-systems

Company Size: None employees

Danaher CorporationMedical Equipment Manufacturing

Beckman Coulter DiagnosticsMedical Equipment Manufacturing

Beckman Coulter Dx North AmericaMedical Equipment Manufacturing

Beckman Coulter Dx BrasilFabricação de instrumentos e materiais para uso médico e odontológico e de artigos ópticos

Beckman Coulter Dx EEMEAتصنيع المعدات الطبية

Beckman Coulter Dx LATAMFabricação de instrumentos e materiais para uso médico e odontológico e de artigos ópticos

Beckman Coulter Dx Asia PacificMedical Equipment Manufacturing

한국벡크만쿨터의료장비 제조

CytivaBiotechnology Research

Pall Medical, part of CytivaMedical Equipment Manufacturing

Cytiva LATAMPesquisa biotecnológica

Pall CorporationManufacturing

Pall - Energy+Machinery Manufacturing

Aria FiltraEnvironmental Services

Pall - Food & BeverageFood and Beverage Services

Pall - AerospaceAviation and Aerospace Component Manufacturing

Pall - Energy+Machinery Manufacturing

Pall - MicroelectronicsAppliances, Electrical, and Electronics Manufacturing

CepheidBiotechnology Research

Leica MicrosystemsMedical Equipment Manufacturing

Leica Microsystems MedicalHospitals and Health Care

Leica BiosystemsMedical Device

Leica Biosystems EMEAMedical Equipment Manufacturing

Beckman Coulter Life SciencesBiotechnology Research

Beckman Coulter Life Sciences India, SWA, METAIBiotechnology Research

Beckman Coulter Life Sciences BrazilBiotechnology Research

Beckman Coulter Life Sciences TASK RegionBiotechnology Research

Beckman Coulter Life Sciences LATAMBiotechnology Research

Beckman Coulter Life Sciences - China生物技术研究

Beckman Coulter Life Sciences RussiaИсследования в сфере биотехнологий

SCIEXBiotechnology Research

SCIEX Food & Environmental Testing SolutionsBiotechnology Research

SCIEX Biopharma & Pharma SolutionsBiotechnology Research

SCIEX Omics SolutionsBiotechnology

SCIEX Forensic Testing SolutionsBiotechnology Research

SCIEX Service & SupportMedical Equipment Manufacturing

SCIEX Clinical ApplicationsMedical Equipment Manufacturing

SCIEX LatinoaméricaPesquisa biotecnológica

Integrated DNA TechnologiesBiotechnology Research

CRISPR genome editing by IDTBiotechnology Research

RadiometerMedical Equipment Manufacturing

AbcamBiotechnology Research

PhenomenexBiotechnology Research

Phenomenex - EMEABiotechnology

Danaher Life SciencesBiotechnology Research

AldevronBiotechnology Research

Beckman Coulter Diagnostics EuropeMedical Equipment Manufacturing

Beckman Coulter Dx TurkeyTıbbi Ekipman İmalatı

Beckman Coulter Dx Eastern EuropeVýroba zdravotnických prostředků

Danaher India Development CenterIT System Custom Software Development

Beckman Coulter Dx China生物技术研究

Danaher DiagnosticsMedical Equipment Manufacturing

Beckman Coulter Dx India & SWAMedical Equipment Manufacturing

HemoCue ABMedical Equipment Manufacturing

IDBSSoftware Development

PolarSoftware Development

GenedataBiotechnology Research

ジーンデータ（株）/ Genedata KKバイオテクノロジー研究

MammotomeMedical Equipment Manufacturing

Molecular DevicesBiotechnology Research

Clone Screening | Molecular DevicesBiotechnology Research

FLIPR Penta Drug Screening | Molecular DevicesBiotechnology Research

Molecular Devices IndiaBiotechnology Research

3D Biology | Molecular DevicesBiotechnology Research

Loading…

High-Content Imaging & Analysis | Molecular Devices Similar Companies

Charles River Laboratories

criver.com

At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all possible. #DrugDiscovery #Biotech #Biotechnology #Pharmaceuticals #CRL

Gilead Sciences

cb gilead.com

At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines

Amgen

amgen.com

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.

CSL

cb csl.com

CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra

Eurofins

cb eurofins.com

Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.

Syneos Health

cb syneoshealth.com

Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.

Agilent Technologies

cb agilent.com

Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.

bioMérieux

biomerieux.com

A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.

Roche

cb roche.com

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation

Loading…

NEWS

High-Content Imaging & Analysis | Molecular Devices CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

October 21, 2025 08:45 AM

Exploring the power of high-content imaging

These techniques capture thousands of cellular features in seconds, translating complex biological activity into measurable patterns and revealing cells as...

Read Article

October 21, 2025 07:00 AM

Real-time, high-throughput super-resolution microscopy via panoramic integration

We introduce super-resolution panoramic integration (SPI), an on-the-fly microscopy technique enabling instantaneous generation of...

Read Article

October 16, 2025 04:32 PM

Screening 3D Spheroids with Automated Imagers

A high-content imaging platform enables high-throughput and high-quality visualization of 3D samples for better cancer research model analysis.

Read Article

October 10, 2025 07:00 AM

Optimizing Parameters for High-throughput Imaging Mass Spectroscopy

In this interview, Yingchan Guo of the University of Florida discusses high-throughput IMS and identifying fatty acyl chains of lipids using...

Read Article

October 07, 2025 07:00 AM

HCS-3DX, a next-generation AI-driven automated 3D-oid high-content screening system

Self-organised three-dimensional (3D) cell cultures, collectively called 3D-oids, include spheroids, organoids and other co-culture models.

Read Article

September 26, 2025 09:38 AM

High-Throughput Imaging Links Microbial Metabolism With Cell Identity | BioScan | Sep/Oct 2022

An imaging platform for investigating microbiomes in medical and environmental samples can perform high-throughput metabolism and identity analyses wi.

Read Article

September 26, 2025 05:32 AM

Achieve High Throughput Imaging

The Nucleus™ microscopy platform provides a complete set of interchangeable hardware modules and software tools, making it ideal for OEMs and la.

Read Article

August 30, 2025 07:00 AM

An effective system for senescence modulating drug development using quantitative high-content analysis and high-throughput screening

Study of cellular senescence is critical in aging research and anti-senescence therapy drug development. Current methods for the evaluation...

Read Article

August 25, 2025 07:00 AM

High content-imaging drug synergy screening identifies specific senescence-related vulnerabilities of mesenchymal neuroblastomas | Cell Death & Disease

Overall, comprehensive high-content imaging screening revealed that neuroblastoma subtypes differ in their lysosomal response to MAPKi treatment...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-50044

SUMMARY

Pronetiqs IntraVUE versions 3.2.1a14 and prior have an inadequate encryption strength vulnerability which could allow an attacker to steal admin credentials via weak hash or a pass-the-hash attack.

Published

Date2026-07-23

Updated

Date2026-07-23

RISK INFORMATION (Score: 6.8)

cvss3

Base Score: 6.8

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:H/I:H/A:N

cvss4

Base Score: 7.6

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:L/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.2

Exploitability

1.6

REFERENCES

https://www.cisa.gov/news-events/ics-advisories/icsa-26-204-04

CVE-2026-44955

SUMMARY

Pronetiqs IntraVUE versions 3.2.1a14 and prior have an exposure of sensitive system information to an unauthorized control sphere vulnerability which could allow for asset discovery by unauthenticated users.

Published

Date2026-07-23

Updated

Date2026-07-23

RISK INFORMATION (Score: 5.3)

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

3.9

REFERENCES

https://www.cisa.gov/news-events/ics-advisories/icsa-26-204-04

CVE-2026-42933

SUMMARY

Pronetiqs IntraVUE versions 3.2.1a14 and prior have an unintended proxy or intermediary vulnerability which could allow an attacker to use an active proxy, which would bypass OT segmentation.

Published

Date2026-07-23

Updated

Date2026-07-23

RISK INFORMATION (Score: 10)

cvss3

Base Score: 10.0

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 10.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

3.9

REFERENCES

https://www.cisa.gov/news-events/ics-advisories/icsa-26-204-04

CVE-2026-40430

SUMMARY

Pronetiqs IntraVUE Versions 3.2.1a14 and prior have a plaintext storage of a password vulnerability that could expose cleartext credentials through the API.

Published

Date2026-07-23

Updated

Date2026-07-23

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

3.9

REFERENCES

https://www.cisa.gov/news-events/ics-advisories/icsa-26-204-04

CVE-2026-28698

SUMMARY

Pronetiqs IntraVUE versions 3.2.1a14 and prior have an exposure of sensitive system information to an unauthorized control sphere vulnerability which could expose the underlying host/share filesystem.

Published

Date2026-07-23

Updated

Date2026-07-23

RISK INFORMATION (Score: 8.6)

cvss3

Base Score: 8.6

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:N/A:N

cvss4

Base Score: 9.2

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

3.9

REFERENCES

https://www.cisa.gov/news-events/ics-advisories/icsa-26-204-04

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…